The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 20, 2025

Filed:

Jul. 28, 2017
Applicant:

Juno Therapeutics, Inc., Seattle, WA (US);

Inventors:

Collin Hauskins, Seattle, WA (US);

Allen Ebens, Seattle, WA (US);

Assignee:

Juno Therapeutics, Inc., Seattle, WA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/52 (2006.01); A61K 38/00 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01); C07K 14/535 (2006.01); C07K 14/54 (2006.01); C07K 14/575 (2006.01); C07K 14/61 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/725 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
C07K 14/521 (2013.01); A61K 48/00 (2013.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07K 14/52 (2013.01); C07K 14/535 (2013.01); C07K 14/54 (2013.01); C07K 14/57554 (2013.01); C07K 14/61 (2013.01); C07K 14/7051 (2013.01); C07K 14/70596 (2013.01); C07K 14/71 (2013.01); C12N 15/62 (2013.01); A61K 38/00 (2013.01); C07K 2319/01 (2013.01);
Abstract

Provided herein are immunomodulatory polypeptides containing first and second submits of a cytokine or a chemokine connected by a joining region containing a targeting moiety that binds to a target molecule. In some aspects, the disclosure further relates to engineered cells and compositions comprising the immunomodulatory polypeptides and methods for their administration to subjects. In some embodiments, the cells engineered to contain the immunomodulatory polypeptide, such as T cells, further contain a genetically engineered antigen receptor that specifically binds to antigens, such as a chimeric antigen receptor (CAR). In some embodiments, features of the polypeptides, engineered cells, and methods provide for improved treatment of diseases or disorders, such as by reducing adverse effects of cytokine or chemokine therapy, or increasing activity, efficacy and/or persistence or decreasing immunogenicity of adoptive cell therapy.


Find Patent Forward Citations

Loading…